Covaxin effective against double mutant strain found in India, shows 78 pc efficacy against mild to severe COVID-19

Covaxin effective against double mutant strain found in India, shows 78 pc efficacy against mild to severe COVID-19

Jagran English

New Delhi | Jagran News Desk: India's indigenous vaccine against COVID-19, Covaxin has shown the efficacy of 78 per cent against mild, moderate and severe COVID-19 cases during phase 3 interim analysis of the results. Bharat Biotech, while announcing the phase 3 trials results of Covaxin also noted that the second interim data of the Phase III study also showed that chances of hospitalisation due to the infectious disease were reduced by 100 per cent after taking the Covaxin jab.

Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per cent against mild, moderate, and severe COVID-19 disease, Bharat Biotech said in a statement, adding that the efficacy against asymptomatic COVID-19 infection was 70 per cent, suggesting decreased transmission in Covaxin recipients.

Disclaimer: This is an automatically aggregated article/story by a computer program and has not been created or edited by Newsdig.in.

World COVID19 Meter

162817722

Cases

142520539

Recovered

3373003

Deaths
Last updated: GMT
Advt
Advt
Advt
sitemap Disclaimer
Newsdig.in 2019